BioWorld

April 12, 2010

View Archived Issues

Common Denominator of Cardiac, Vascular Disease

Biogen, Gilead, Others Warned About Misleading Promotions

Other News To Note

Stock Movers

Financings Roundup

Clinic Roundup

U.S. Patent Disclosures

Bench Press

Tengion Prices $30M IPO Despite Early Stage, High-Risk Programs

Tengion Inc., which priced a $30 million initial public offering on Friday, was easily the earliest-stage biotech to try its luck in the current IPO window. (BioWorld Today) Read More

FDA Rejects CTI Lymphoma Drug; Firm to Seek Compassionate Use

Today's news in brief

BioWorld

BioWorld briefs for April 2, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026

Hematopoietic stem cell research points to leukemia’s early roots

BioWorld Science

Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...

Illustration of a nerve cell with DNA double helix

Molecular signatures show subtypes in neurodegenerative diseases

BioWorld Science

Parkinson’s disease is a progressive neurodegenerative disorder best known for its motor symptoms. However, a proportion of patients also develop dementia as the...

Hengrui discovers new Nav1.8 blockers

BioWorld Science

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...